Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026)

Rani Therapeutics Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $161000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 35.86% year-over-year to $161000.0 in Q1 2026; TTM through Mar 2026 was $810000.0, a 21.44% decrease from a year earlier, with the FY2025 full-year figure at $900000.0, down 12.45% from the prior year.
• Depreciation & Amortization (CF) eased to $161000.0 in Q1 2026 per RANI's latest filing, from $186000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $266000.0 in Q4 2024 and bottomed at $111000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $218000.0 (2023), against an average of $203470.6.
• Across the five-year window, Depreciation & Amortization (CF) jumped 69.37% in 2023 and sank 35.86% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $174000.0 in 2022, then surged by 30.46% to $227000.0 in 2023, then climbed by 17.18% to $266000.0 in 2024, then plunged by 30.08% to $186000.0 in 2025, then retreated by 13.44% to $161000.0 in 2026.
• Per Business Quant, the three latest RANI Depreciation & Amortization (CF) figures stand at $161000.0 (Q1 2026), $186000.0 (Q4 2025), and $223000.0 (Q3 2025).